ABSTRACT
OBJECTIVES: Our primary aim was to validate the Liverpool Peritonsillar abscess Score (LPS) externally in a new patient cohort. Our secondary aim was to modify the LPS in the light of the COVID-19 pandemic to produce a no-examination variant for use in this instance. DESIGN: Prospective multicentre external validation study. SETTING: Six different secondary care institutions across the United Kingdom. PARTICIPANTS: Patients over 16 years old who were referred to ENT with any uncomplicated sore throat such a tonsillitis or peritonsillar abscess (PTA). MAIN OUTCOME MEASURES: Sensitivity, specificity, positive predictive value and negative predictive value for both the original LPS model and the modified model for COVID-19. RESULTS: The LPS model had sensitivity and specificity calculated at 98% and 79%, respectively. The LPS has a high negative predictive value (NPV) of 99%. The positive predictive value (PPV) was slightly lower at 63%. Receiver operating characteristic (ROC) curve, including the area under the curve (AUROC), was 0.888 which indicates very good accuracy. CONCLUSIONS: External validation of the LPS against an independent geographically diverse population yields high NPV. This may support non-specialist colleagues who may have concerns about mis-diagnosing a PTA. The COVID-19 modification of the LPS has a similar NPV, which may be of use where routine oral examination is to be avoided during the COVID-19 pandemic.
Subject(s)
COVID-19/epidemiology , Disease Management , Pandemics , Peritonsillar Abscess/diagnosis , SARS-CoV-2 , Adolescent , Adult , Aged , Aged, 80 and over , Comorbidity , Female , Humans , Male , Middle Aged , Peritonsillar Abscess/epidemiology , Prospective Studies , ROC Curve , United Kingdom/epidemiology , Young AdultSubject(s)
Carcinoma, Small Cell/pathology , Lung Neoplasms/pathology , Pulmonary Artery/pathology , Solitary Pulmonary Nodule/pathology , Aged , Biopsy, Needle , Carcinoma, Small Cell/diagnosis , Carcinoma, Small Cell/therapy , Combined Modality Therapy , Diagnosis, Differential , Female , Health Services Needs and Demand , Humans , Immunohistochemistry , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Neoplasm Staging , Pulmonary Artery/diagnostic imaging , Radiography , Solitary Pulmonary Nodule/diagnosis , Treatment OutcomeABSTRACT
You may be struggling with contract issues with a vendor. Or maybe you're contemplating the pros and cons of working with outsource, at-home, or overseas transcriptionists. It's a fact: if transcription processes aren't working efficiently, the entire HIM department may be adversely affected. Factor in additional concerns such as data capture for electronic health records, compliance, and patient safety, and the importance of ensuring quality and cost-efficient transcription becomes even more apparent. To help you answer some of these questions, the Journal of AHIMA is launching a four-part series dedicated to transcription issues from the HIM professional's point of view. In this issue, we begin with MTIA president Scott Faulkner's overview of the industry and where it's going next. In upcoming issues, other experts will look at controlling cost and monitoring quality, navigating new technologies, and dealing with contract-related issues.
